GALAPAGOS NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.68 EUR | +0.45% |
|
-1.84% | -27.87% |
ETFs positioned on Galapagos NV
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.28% | 22 M€ | -1.21% | ||
| 0.03% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 1 M€ | -.--% | - | |
| 0.00% | 29 M€ | -3.48% | - | |
| 0.00% | 152 M€ | -3.56% | - | |
| 0.00% | 26 M€ | -4.26% | - |
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Calendar
2024-04-30
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
26.68
EUR
Average target price
38.43
EUR
Spread / Average Target
+44.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.87% | 1.88B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- GLPG Stock
- Funds and ETFs Galapagos NV
